AAA
ALPN

Affinity Asset Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Affinity Asset Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-118,891
Closed -$1.22M – 97
2023
Q2 		$1.22M Sell
118,891
-129,000
-52% -$1.16M 0.43% 46
2023
Q1 		$1.91M Hold
247,891
– – 0.63% 42
2022
Q4 		$1.82M Buy
247,891
+137,891
+125% +$881K 0.71% 43
2022
Q3 		$792K Buy
+110,000
New +$907K 0.22% 53

Other funds holding ALPN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Affinity Asset Advisors's ALPN Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2023, closing a stake of 118,891 shares — an estimated $1.22M sold.

Affinity Asset Advisors first reported a position in ALPN in Q3 2022 and held it in 4 quarters. The position peaked at $1.91M in Q1 2023. 88 funds tracked by Wall St. Rank hold ALPN as of Q3 2023.

  • Affinity Asset Advisors reported no remaining Alpine Immune Sciences Inc position as of Q3 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 118,891 Alpine Immune Sciences Inc shares in Q3 2023, an estimated $1.22M.
  • Affinity Asset Advisors first reported a position in Alpine Immune Sciences Inc in Q3 2022 and held it in 4 quarters.
  • Affinity Asset Advisors's Alpine Immune Sciences Inc position peaked at $1.91M in Q1 2023.
  • 88 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.